Eugeroic
| Eugeroic | |
|---|---|
N06B | |
| Legal status | |
| In Wikidata |
Eugeroics (originally "eugrégorique" or "eugregoric"),
Modafinil and armodafinil are each thought to act as selective, weak, atypical dopamine reuptake inhibitors (DRI),[2][3] whereas adrafinil acts as a prodrug for modafinil. Other eugeroics include solriamfetol, which acts as a norepinephrine–dopamine reuptake inhibitor (NDRI),[6][7] and pitolisant, which acts as a histamine 3 (H3) receptor antagonist/inverse agonist.[8][9][10]
Recent research
Cephalon, the original U.S. market rights holder of modafinil, has demonstrated initiative in the development of a successor to the prototypical eugeroic.[11] Of the more than twenty compounds preclinically tested in Cephalon's three-part drug discovery series, the compound fluorenol was selected as a lead. Fluorenol was found to induce wakefulness to a greater degree than modafinil, despite possessing a lower affinity for the dopamine transporter.[12]
All currently marketed eugeroics are classified as central nervous system stimulants and possess some (attenuated) stimulant-like properties.[13][14] It is expected that future developments will further distinguish eugeroics from classical CNS stimulants.[15][11]
Examples
Marketed
- Armodafinil (Nuvigil)
- Modafinil (Provigil)
- Pitolisant (Wakix)[16]
- Solriamfetol (Sunosi)[14]
Discontinued
- Adrafinil (Olmifon)
Never marketed
- Flmodafinil (CRL-40,940)
- Fluorafinil (CRL-40,941)
- Fluorenol
- Methylbisfluoromodafinil
In development
References
- ISSN 1080-563X.
- ^ a b c d "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Retrieved 16 August 2015.
- ^ a b c d "Nuvigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. April 2015. Retrieved 16 August 2015.
- ^ "Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin" (PDF). American Academy of Sleep Medicine (AASM). September 2007.
- S2CID 40801601.
- PMID 15361919.
- ISBN 978-0-521-75852-9.
- PMID 21615387.
- PMID 28449891.
- S2CID 36336966.
- ^ PMID 22264475.
- PMID 22546675.
- S2CID 36336966.
- ^ a b "What is SUNOSI® (solriamfetol) Treatment ? | SUNOSI® for Patients". www.sunosi.com. Retrieved 2020-01-03.
- PMID 22375280.
- ^ "How WAKIX Works | WAKIX® (pitolisant) tablets". wakix.com. Retrieved 2020-01-03.
- ^ "New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1". www.takeda.com. Retrieved 2019-12-06.
- ^ "Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances. - Patent EP-3792252-A1 - PubChem". pubchem.ncbi.nlm.nih.gov. Retrieved 2022-09-26.